Connect Biopharma Holdings Limited Stock price

Equities

CNTB

US2075231017

Biotechnology & Medical Research

Delayed Nasdaq 03:17:23 2024-03-28 pm EDT 5-day change 1st Jan Change
1.724 USD +7.08% Intraday chart for Connect Biopharma Holdings Limited +37.90% +44.92%
Sales 2023 * 150M 20.79M Sales 2024 * 610M 84.36M Capitalization 641M 88.69M
Net income 2023 * -326M -45.12M Net income 2024 * -215M -29.75M EV / Sales 2023 * -2.62 x
Net cash position 2023 * 1.03B 143M Net cash position 2024 * 830M 115M EV / Sales 2024 * -0.31 x
P/E ratio 2023 *
-1.95 x
P/E ratio 2024 *
-2.97 x
Employees 100
Yield 2023 *
-
Yield 2024 *
-
Free-Float 56.35%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Connect Biopharma Holdings Limited

1 day+21.05%
1 week+28.80%
Current month+36.44%
1 month+27.78%
3 months+61.00%
6 months+120.55%
Current year+36.44%
More quotes
1 week
1.18
Extreme 1.18
1.65
1 month
1.10
Extreme 1.1
1.65
Current year
0.90
Extreme 0.9
1.65
1 year
0.53
Extreme 0.5347
2.84
3 years
0.53
Extreme 0.5347
29.27
5 years
0.53
Extreme 0.5347
29.27
10 years
0.53
Extreme 0.5347
29.27
More quotes
Managers TitleAgeSince
Founder 61 15-11-22
Founder 60 12-04-30
Director of Finance/CFO 52 21-11-21
Members of the board TitleAgeSince
Director/Board Member 55 21-08-22
Director/Board Member 66 20-11-30
Director/Board Member 61 20-11-30
More insiders
Date Price Change Volume
24-03-28 1.724 +7.08% 445 137
24-03-27 1.61 +21.05% 367,829
24-03-26 1.33 +4.72% 134,388
24-03-25 1.27 -0.78% 111,161
24-03-22 1.28 +3.23% 68,139

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the treatment of T cell-driven inflammatory diseases. The Company's lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4Ra) in development for the treatment of atopic dermatitis and asthma. Its second advanced product candidate, CBP-307, is a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis (UC). The Company's third product candidate, CBP-174, is a peripherally acting antagonist of histamine receptor 3, in development for the treatment of pruritus associated with atopic dermatitis (AD). It has clinical development activities in the United States, the People's Republic of China (PRC), Europe, and Australia and operations in those geographies, as well as Hong Kong. Its subsidiaries include Connect Biopharma HongKong Limited, Connect Biopharm LLC and others.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.61 USD
Average target price
6.5 USD
Spread / Average Target
+303.73%
Consensus
  1. Stock
  2. Equities
  3. Stock Connect Biopharma Holdings Limited - Nasdaq